[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100400870":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":130,"collaborators":43,"id":133,"slug":134,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":43,"enrollmentInfo":143,"targetDuration":43,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":43,"overallStatus":52,"whyStopped":43,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"The Catholic University of Korea","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ezetimibe 10 mg plus rosuvastatin 5 mg","EXPERIMENTAL","Rosuzet 5\u002F10 mg , once a day for 24 months",[13],"Drug: Ezetimibe 10mg + Rosuvastatin 5mg",{"label":15,"type":16,"description":17,"interventionNames":18},"rosuvastatin 20 mg only","ACTIVE_COMPARATOR","Any brand drugs of rosuvastatin 20mg, once a day for 24 months",[19],"Drug: Rosuvastatin 20mg",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ezetimibe 10mg + Rosuvastatin 5mg","Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin",[9],[27],"Rosuzet 10\u002F5 mg",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Rosuvastatin 20mg","20mg of Rosuvastatin as a standard treatment for AMI patients",[15],[33],"Crestor 20mg",[35],{"name":36,"affiliation":37,"role":38},"Kiyuk Chang, MD,PhD","Seoul St. Mary's Hospital","STUDY_CHAIR",[40,45],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","82-10-9175-2076",null,"kiyuk@catholic.ac.kr",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Eun Ho Choo, MD","82-10-8500-4569","cmcchu@catholic.ac.kr",[50,65,76,87,98,109,122],{"facility":51,"status":52,"city":53,"state":54,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Bucheon St.Mary Hospital","RECRUITING","Bucheon-si","Gyeonggido","South Korea",{"type":57,"coordinates":58},"Point",[59,60],126.78306,37.49889,{"lat":60,"lon":59},[63],{"name":64,"role":41,"phone":43,"phoneExt":43,"email":43},"Hee Yeol Kim, M.D.",{"facility":66,"status":52,"city":67,"state":54,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"St.Vincent's Hospital","Suwon",{"type":57,"coordinates":69},[70,71],127.00889,37.29111,{"lat":71,"lon":70},[74],{"name":75,"role":41,"phone":43,"phoneExt":43,"email":43},"Ki-Dong Yoo, M.D.",{"facility":77,"status":52,"city":78,"state":54,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Uijeongbu St.Mary's Hospital","Uijeongbu-si",{"type":57,"coordinates":80},[81,82],127.0474,37.7415,{"lat":82,"lon":81},[85],{"name":86,"role":41,"phone":43,"phoneExt":43,"email":43},"Chan Joon Kim, M.D.",{"facility":88,"status":52,"city":89,"state":43,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Daejeon St.Mary's Hospital","Daejeon",{"type":57,"coordinates":91},[92,93],127.38493,36.34913,{"lat":93,"lon":92},[96],{"name":97,"role":41,"phone":43,"phoneExt":43,"email":43},"Man Won Park, M.D.",{"facility":99,"status":52,"city":100,"state":43,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Incheon St.Mary's Hospital","Incheon",{"type":57,"coordinates":102},[103,104],126.70515,37.45646,{"lat":104,"lon":103},[107],{"name":108,"role":41,"phone":43,"phoneExt":43,"email":43},"Doo Soo Jeon, M.D.",{"facility":110,"status":52,"city":111,"state":43,"zip":112,"country":55,"countryCode":43,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Seoul St.Mary's Hospital","Seoul","137-701",{"type":57,"coordinates":114},[115,116],126.9784,37.566,{"lat":116,"lon":115},[119],{"name":120,"role":121,"phone":43,"phoneExt":43,"email":43},"Kiyuk Chang, M.D.","PRINCIPAL_INVESTIGATOR",{"facility":123,"status":52,"city":111,"state":43,"zip":43,"country":55,"countryCode":43,"cosmosGeoPoint":124,"geoPoint":126,"contacts":127},"Yeouido St.Mary Hospital",{"type":57,"coordinates":125},[115,116],{"lat":116,"lon":115},[128],{"name":129,"role":41,"phone":43,"phoneExt":43,"email":43},"Chul-Soo Park, M.D.",{"type":131,"investigatorFullName":36,"investigatorTitle":132,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"SPONSOR_INVESTIGATOR","Professor of Medicine","100400870","phase-4-low-dose-rosuvastatin-plus-ezetimibe-versus-high-dose-rosuvastatin-in-ami-100400870",false,"NCT04499859","Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI","A Prospective, Multicenter, Randomized, Open-label Trial to Compare Low-dose ROSUvastatin Plus eZETimibe Versus High-dose Rosuvastatin in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention","ROSUZET-AMI","Inclusion Criteria:\n\n1. Adults Aged 19 and up\n2. Patients diagnosed with myocardial infarction (both ST segment elevation and non-ST segment elevation) who were treated with percutaneous coronary intervention (Myocardial infarction defined as in the 4th Universal Definition of Myocardial Infarction)\n3. For female patients who are of childbearing age, subjects that agreed on taking mandatory pregnancy test\n4. Patients who agreed and signed on the informed consent form\n\nExclusion Criteria:\n\n1. Patients with life expectancy of a year or less due to malignancy\n2. Patients with chronic liver disease\n3. Patients with sensitivity to active ingredient of the research drugs (ezetimibe and\u002For rosuvastatin) or patients who are prohibited to take ezetimibe and\u002For rosuvastatin.\n4. Pregnant and\u002For breastfeeding\n5. Female patients who are unable to use any means of contraception\n6. Patients receiving hemodialysis, peritoneal dialysis patients and\u002For kidney transplant patients, due to end stage renal disease\n7. Patients who participated in other clinical trial(s) within 3 months from the screening (except non-interventional observational study)\n8. Patients considered inappropriate for the study for any other reason(s) by the inspector(s)","ALL","19 Years",{"count":144,"type":145},3548,"ESTIMATED","INTERVENTIONAL",[148],"PHASE4","Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.\n\nThis trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and ezetimibe among patients with acute myocardial infarction who went through percutaneous coronary intervention at decreasing major adverse cardiac events compared to the efficacy of single use of high dose rosuvastatin.",[151,152,153],"Myocardial Infarction","Statin Adverse Reaction","HMG-CoA Reductase Inhibitor Toxicity","2025-07-28",{"date":156,"type":157},"2025-07-30","ACTUAL",{"date":159,"type":157},"2020-10-01",{"date":161,"type":145},"2027-08-30",{"name":36,"class":6},7]